 | Up a level |
O'Donoghue, Michelle L., Fazio, Sergio, Giugliano, Robert P., Stroes, Erik S. G., Kanevsky, Estella, Gouni-Berthold, Ioanna, Im, KyungAh, Pineda, Armando Lira, Wasserman, Scott M., Ceska, Richard, Ezhov, Marat V., Jukema, J. Wouter, Jensen, Henrik K., Tokgozoglu, S. Lale, Mach, Francois, Huber, Kurt, Sever, Peter S., Keech, Anthony C., Pedersen, Terje R. and Sabatine, Marc S. (2019). Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial. Circulation, 139 (12). S. 1483 - 1493. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1524-4539
Sever, Peter, Gouni-Berthold, Ioanna, Keech, Anthony, Giugliano, Robert, Pedersen, Terje R., Im, KyungAh, Wang, Huei, Knusel, Beat, Sabatine, Marc S. and O'Donoghue, Michelle L. . LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Eur. J. Prev. Cardiol.. LONDON: SAGE PUBLICATIONS LTD. ISSN 2047-4881